BLLN

BillionToOne is a molecular-diagnostics company with prenatal screening and oncology (liquid-biopsy) test lines, and its growth is genuinely exceptional: revenue doubled to $305M in FY2025 (from $71.7M in FY2023), gross profit rose 157.6% to $208M, and the company crossed into profitability with $7.45M of net income — its first profit after losses of -$82.7M and -$41.6M in the prior two years. The 68.3% gross margin and the 10-K's emphasis on growing operational headcount far slower than test volume point to real, widening operating leverage. The balance sheet is pristine for a young growth company: $496M cash, only $57.2M long-term debt, $480M equity and a 0.32x liabilities/equity ratio, with positive operating cash flow of $24.6M.

The business quality is high, but two risks define the call. First, the 10-K notes that more than 90% of revenue comes from third-party payors, so ASPs and revenue hinge on maintaining and expanding insurance coverage and reimbursement — a structurally uncertain and payor-by-payor process that could pressure pricing. Second, success depends on continued clinical adoption by physicians and inclusion in practice guidelines in competitive prenatal and oncology testing markets.